The SPIRIT H2H is the first H2H trial in PsA and it was designed to evaluate the superiority of Taltz versus adalimumab in the treatment of PsA in biologic-naïve patients with the primary objective of assessing the proportion of patients simultaneously achieving ACR50 and PASI 100 at Week 241.
Taltz, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to, one or more disease-modifying anti-rheumatic drug (DMARD) therapies2.
PP-IX-AT-0672, PP-IX-CZ-0380, PP-IX-HU-0066, PP-IX-RO-0493
1 Mease PJ, et al. Ann Rheum Dis. 2019;78:261-262. LB0005 Oral Presentation and Poster Presented at: European League Against Rheumatism (EULAR); Madrid, Spain; 12-15 June 2019.
2Taltz Summary of Product Characteristics. Eli Lilly and Company.
This webinar has been developed, organised and funded by Eli Lilly and Company Ltd. Intended for Healthcare Professionals only. Lilly products will be discussed at this meeting.
Adverse events and product complaints should be reported. Reporting forms and further information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store, or Ireland: www.hpra.ie. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000, or Lilly Ireland on 01 664 0446.